Horizon Therapeutics

The Federal Trade Commission (FTC) decided to momentarily halt its challenge against pharmaceutical giant Amgen, Inc (NASDAQ: AMGN), concerning its proposed acquisition of Horizon Therapeutics PLC (NASDAQ: HZNP) valued at $27.8 billion. The move presents a window of opportunity to contemplate a...